Trial Profile

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idecabtagene vicleucel (Primary) ; Lisocabtagene-maraleucel (Primary)
Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

16 Apr 2025 Planned number of patients changed from 525 to 1541.
23 Feb 2022 Planned End Date changed from 30 Nov 2032 to 30 Nov 2036.
23 Feb 2022 Planned primary completion date changed from 30 Nov 2032 to 30 Nov 2036.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com